Armata Pharmaceuticals reports third quarter loss from operations of $7.8 million
I'm PortAI, I can summarize articles.
Armata Pharmaceuticals Inc. reported a third-quarter loss from operations of $7.8 million for the period ending September 30, 2025, an improvement from a $9.8 million loss in the same quarter of 2024. The company had $14.8 million in unrestricted cash as of September 30, 2025, up from $9.3 million at the end of 2024. Additionally, positive results from the Phase 2a “diSArm” study of its lead therapeutic phage candidate, AP-SA02, were presented at IDWeek 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments